SG169992A1 - Low flush niacin formulation - Google Patents

Low flush niacin formulation

Info

Publication number
SG169992A1
SG169992A1 SG201101094-9A SG2011010949A SG169992A1 SG 169992 A1 SG169992 A1 SG 169992A1 SG 2011010949 A SG2011010949 A SG 2011010949A SG 169992 A1 SG169992 A1 SG 169992A1
Authority
SG
Singapore
Prior art keywords
low flush
release
niacin formulation
niacin
tablets
Prior art date
Application number
SG201101094-9A
Other languages
English (en)
Inventor
Jose G Rocca
Yucun Zhu
Eugenio A Cefali
Original Assignee
Abbott Respiratory Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Respiratory Llc filed Critical Abbott Respiratory Llc
Publication of SG169992A1 publication Critical patent/SG169992A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
SG201101094-9A 2006-02-17 2007-02-15 Low flush niacin formulation SG169992A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77433906P 2006-02-17 2006-02-17

Publications (1)

Publication Number Publication Date
SG169992A1 true SG169992A1 (en) 2011-04-29

Family

ID=38421253

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201101094-9A SG169992A1 (en) 2006-02-17 2007-02-15 Low flush niacin formulation

Country Status (14)

Country Link
US (1) US20080050429A1 (fr)
EP (1) EP1996167A2 (fr)
JP (1) JP2009527477A (fr)
KR (1) KR20090015890A (fr)
CN (2) CN102940613A (fr)
AU (1) AU2007239057A1 (fr)
BR (1) BRPI0708059A2 (fr)
CA (2) CA2569776A1 (fr)
IL (1) IL193472A0 (fr)
MX (1) MX2008010578A (fr)
NZ (1) NZ570581A (fr)
RU (1) RU2467750C2 (fr)
SG (1) SG169992A1 (fr)
WO (1) WO2007120385A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
WO2008097535A2 (fr) * 2007-02-08 2008-08-14 Merck & Co., Inc. Procédé de traitement de l'athérosclérose, des dyslipidémies et d'états pathologiques apparentés
US20100305074A1 (en) * 2007-04-04 2010-12-02 Hight H Thomas Niacin-based pharmaceutical compositions
US8404275B2 (en) * 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
RU2010151944A (ru) * 2008-05-20 2012-06-27 Серенис Терапьютикс С.А. (Fr) Ниацин и нспвс для комбинированной терапии
EP2296709A4 (fr) * 2008-06-02 2012-02-01 Reddys Lab Ltd Dr Formulations de niacine à libération modifiée
WO2011102506A1 (fr) * 2010-02-22 2011-08-25 第一三共株式会社 Préparation solide à libération prolongée pour usage oral
CN104105478A (zh) 2011-10-28 2014-10-15 维塔利斯公司 抗发红组合物
US10278925B2 (en) 2012-01-04 2019-05-07 Wellesley Pharmaceuticals, Llc Delayed-release formulations, methods of making and use thereof
AU2012363788B2 (en) * 2012-01-04 2017-03-09 Wellesley Pharmaceuticals, Llc Delayed-release formulation for reducing the frequency of urination and method of use thereof
US9456982B2 (en) 2014-05-18 2016-10-04 Be-Warm Llc Solid formulations of niacin to counteract cold extremities
SG11201704332YA (en) * 2014-12-02 2017-06-29 Minerva Neurosciences Inc Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
JP2020525436A (ja) 2017-06-21 2020-08-27 ミネルバ・ニューロサイエンシズ・インコーポレイテッド 胃耐性制御放出経口剤形

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3674836A (en) * 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4027009A (en) * 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
JPS5612114B2 (fr) * 1974-06-07 1981-03-18
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
PT1017390E (pt) * 1997-07-31 2007-07-24 Kos Life Sciences Inc Comprimido revestido que compreende ácido nicotínico ou um composto metabolizado a ácido nicotínico sob uma forma de libertação prolongada, e um revestimento que contém um inibidor da hmg-coa-redutase sob uma forma de libertação imediata.
WO2000033818A1 (fr) * 1998-12-11 2000-06-15 Nostrum Pharmaceuticals, Inc. Comprime a liberation prolongee contenant un hydrocolloide et un ether de cellulose
CA2598273A1 (fr) * 2005-02-17 2006-08-24 Merck & Co., Inc. Methode de traitement de l'atherosclerose, de dyslipidemies et de troubles lies

Also Published As

Publication number Publication date
BRPI0708059A2 (pt) 2011-05-17
EP1996167A2 (fr) 2008-12-03
CA2642851A1 (fr) 2007-10-25
CA2642851C (fr) 2011-01-25
NZ570581A (en) 2011-11-25
WO2007120385A3 (fr) 2008-01-03
RU2008137229A (ru) 2010-03-27
IL193472A0 (en) 2009-05-04
JP2009527477A (ja) 2009-07-30
CA2569776A1 (fr) 2007-08-17
MX2008010578A (es) 2009-01-22
RU2467750C2 (ru) 2012-11-27
AU2007239057A1 (en) 2007-10-25
CN101420938A (zh) 2009-04-29
US20080050429A1 (en) 2008-02-28
WO2007120385A2 (fr) 2007-10-25
KR20090015890A (ko) 2009-02-12
CN102940613A (zh) 2013-02-27

Similar Documents

Publication Publication Date Title
SG169992A1 (en) Low flush niacin formulation
NZ619520A (en) Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
UA86831C2 (uk) Композиція таблетки пролонгованого вивільнення, яка містить праміпексол або його фармацевтично прийнятну сіль, спосіб її виготовлення та її застосування
EP2079443A4 (fr) Préparations inhalées, à double action permettant d'obtenir un profil de libération immédiate et prolongée
EP3272337A3 (fr) Comprimés
MX2009007254A (es) Composiciones de tableta en tableta.
EP1742630A4 (fr) Combinaison d'un inhibiteur de la pompe a protons, d'un agent tampon et d'un agent prokinetique
AU2010308458A8 (en) Orally transformable tablets
EP2054380B8 (fr) Inhibiteurs de serine protease de type trypsine, leur fabrication et leur utilisation
IL180872A0 (en) Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv
WO2007036952A3 (fr) Nouvelle forme posologique a liberation soutenue
HK1107672A1 (en) Conveniently implantable sustained release drug compositions
IL182686A0 (en) New modified release tablet formulations for proton pump inhibitors
IL196108A0 (en) Active agent formulations, methods of making, and methods of use
SG170044A1 (en) Ocular allergy treatments
PL1973423T3 (pl) Preparat zawierający kompozycję zawierającą polifenole i izomaltulozę
TW200833378A (en) Disinfecting tablet
WO2007095258A3 (fr) compositions comprenant un rhamnolipide et leurs procedes d'utilisation
HK1115584A1 (en) Benzimidazole derivative and use thereof
WO2006121522A3 (fr) Capteurs et pompes implantables, agents anticicatrisants, et compositions therapeutiques
WO2008089488A3 (fr) Dispositifs intravaginaux biodégradables pour la délivrance d'agents thérapeutiques
PT1962877T (pt) Extratos de phaseolus vulgaris precipitados com etanol, a sua utilização e formulações
WO2007141743A3 (fr) Forme pharmaceutique de comprimé comprenant de la cétirizine et de la pseudoéphédrine
EP1837026A4 (fr) Agent therapeutique pour la fonction hepatique
WO2007099555A3 (fr) Compositions pharmaceutiques contenant de l'irbésartan